This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Damages Awarded In J&J's DePuy Hip Implant Case

"They wanted to play Russian roulette with patients. This defendant didn't care about patient safety," Panish said.

Defense attorneys denied Kransky's claims and argued he had a host of pre-existing health ailments and the hip implant didn't make him worse.

The hip joint was sold for eight years to more than 90,000 people worldwide. New Brunswick, N.J.-based Johnson & Johnson stopped making the product in 2009 and recalled it the next year.

The artificial part is meant to replace deteriorated joints causing severe pain and limiting mobility, and is generally expected to last 10 to 20 years. With the DePuy hip implant, one in eight patients needed theirs replaced within five years.

Attorneys representing the patients claim J&J knew about the problems in 2008. The company has denied those allegations.

Johnson & Johnson, the world's biggest provider of health care products, has issued more than 30 product recalls since 2009. Most have involved nonprescription medicines such as adult and children's Tylenol and Motrin, but other recalls were for prescription drugs for conditions such as epilepsy or for contact lenses.

Johnson & Johnson shares rose 44 cents to $78.19 Friday.

Copyright 2011 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,092.06 +54.09 0.30%
S&P 500 2,113.12 +4.20 0.20%
NASDAQ 5,069.9620 +9.7160 0.19%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs